The "Biomarkers of relapse and therapeutic response in addictions and mood disorders" team develops research on mood disordersand addiction both at the clinical and fundamental level (ranked A, AERES 2013, creation 01/01/2014).The objective is to identifyclinical, biological, genetic or imaging-based markers of the response to psychotropic drugs (in the context of drug abuse or during thetreatment for mood disorders or pain management). These markers will allow us to better predict the response (therapeutic and sideeffects) in order to improve the therapeutic monitoring of patients.
Our present work started from our observation that serotonin tone can be controlled by a feed-forward mechanism via 5-HT2B receptors. Recent independent investigations and our unpublished results indicate that this same serotonergic receptor may also impact local dopamine levels. The absence of 5-HT2B receptors, DA-targeting drugs induce a reduced increase in extracellular DA in NAcc, but a normal increase in dorsal striatum, thus an imbalance that could underlie addictive behaviors. Other unpublished evidence (in collaboration with D.
The general interest of the lab is to dissect the neuronal circuits implicated in reward learning and to understand how drugs co-opt these connections.
Goal directed actions, aimed to obtain a reward, motivate our behaviors and influence our decisions.
The overall goal of our research is to decipher the mechanisms involved in major mental health problems: psychosis, depression, bipolar disorder, addiction.
The main goal of our team is to unravel the intracellular events that govern cerebral plasticity and long-term behavioral alterations. We study their roles in gene regulations, neuronal adaptations in physiological (learning and memory) or pathophysiological (exposure to addictive drugs, neurodegenerative diseases) contexts. More specifically, we study these mechanisms within the striatum, the major input structure of the basal ganglia, which plays key roles in action selection and execution of movements as well as in reward-dependent learning and cognition.
Over the past 4 years, we have been studying psychiatric disorders and addictions that are prevalent and have a high social cost. We use magnetic resonance imaging and positron emission tomography to capture brain images in severely impaired patients and to assess the effects of treatment on brain function. We are based in the Service Hospitalier Frédéric Joliot (SHFJ), Orsay. We also collaborate with a network of psychiatrists within the Paris area and collaborate on large data sets with North Europe research teams.